Understand the importance of biomarkers in the management of your patients with NSCLC
of patients like yours may have an oncogenic MET alteration1,2
of patients like yours may have an oncogenic METex14 skipping
of patients like yours may have a high-level oncogenic METamp alteration1,2
Studies show that the MET pathway is critical for normal biologic processes, including embryonic and organ development, tissue repair and wound healing.1,3,4
Dysregulation of the MET pathway can occur through many mechanisms, including:1,3,4
With MET receptor overexpression observed in 35–72% of NSCLC tumors.1
MET alterations (namely, METex14 skipping and METamp) occur in up to 6% of patients with NSCLC, and correlate independently with advanced disease stage.3,4 3–4% of patients like yours with NSCLC may harbor a METex14 skipping alteration, correlating with a poorer
prognosis.1,2,5,6 The presence of METex14 skipping is mutually exclusive to commonly tested oncogenic drivers, such as RET, BRAF, ALK, EGFR and ROS1.7,8
Oncogenic MET alterations cause aberrant activation of the MET pathway, driving tumor growth and are associated with acquired resistance.3,4,11
Patients with NSCLC harboring MET alterations have a higher association with advanced stage disease.7 A multivariate survival analysis assessing overall survival in patients with METex14 patients (n=18) or METamp (n=8) NSCLC demonstrated that those with either of these alterations had a significantly shorter OS compared to those without.12
OS, overall survival
1. Salgia R. Mol Cancer Ther 2017; 16:555–565.
2. Ikeda S et al. J Hematol Oncol 2018; 11:76.
3. Drilon A et al. J Thorac Oncol 2017; 12:15–26.
4. Wu YL et al. Cancer Treat Rev 2017; 61:70–81.
5. Wang Q et al. J Hematol Oncol 2019; 12:63.
6. Sterlacci W et al. Virchows Arch 2017; 471:49–55.
7. Awad MM et al. Lung Cancer 2019; 133:96–102.
8. Frampton GM et al. Cancer Discov 2015; 5:850–859.
9. Pakkala S, Ramalingam SS. JCI Insight 2018; 3:e120858.
10. Rossell R, Karachaliou N. Lancet 2016; 387:1354–1356.
11. Kim EK et al. Clin Lung Cancer 2019; 20:e123–32.
12. Tong JH et al. Clin Cancer Res 2016; 22:3048–3056.